InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
68,483.89
(
-1.19%
)
Post# of 253510
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

NP1986

Send PM Follow Ignore
Followers 6
Posts 541
Boards Moderated 0
Alias Born 06/07/2011

NP1986

Re: dav1234 post# 155661

Tuesday, 01/22/2013 12:09:53 PM

Tuesday, January 22, 2013 12:09:53 PM

Post# of 253510
US sales of Zytiga decreased from $136m in Q3 to $114m in Q4. Overall sales were flat (~265m). In the Q&A, JNJ attributed this primarily to their patient assistance program, and said that Zytiga scripts are still growing. However, the remarks were not specific to any region.

Astellas will report earnings on Feb 4th, so it will be interesting to see how Xtandi is doing.



Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up